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Background: TP53 gene mutations can lead to the expression of a dysfunctional protein that in turn may enable
genetically unstable cells to survive and change into malignant cells. Mutant p53 accumulates early in cells and can
precociously induce circulating anti-p53 antibodies (p53Abs); in fact, p53 overexpression has been observed in
pre-neoplastic lesions, such as bronchial dysplasia, and p53Abs have been found in patients with Chronic
Obstructive Pulmonary Disease, before the diagnosis of lung and other tobacco-related tumors.
Methods: A large prospective study was carried out, enrolling non-smokers, ex-smokers and smokers with or
without the impairment of lung function, to analyze the incidence of serum p53Abs and the correlation with
clinicopathologic features, in particular smoking habits and impairment of lung function, in order to investigate
their possible role as early markers of the onset of lung cancer or other cancers. The p53Ab levels were evaluated
by a specific ELISA in 675 subjects.
Results: Data showed that significant levels of serum p53Abs were present in 35 subjects (5.2%); no difference was
observed in the presence of p53Abs with regard to age and gender, while p53Abs correlated with the number of
cigarettes smoked per day and packs-year. Furthermore, serum p53Abs were associated with the worst lung
function impairment. The median p53Ab level in positive subjects was 3.5 units/ml (range 1.2 to 65.3 units/ml). Only
fifteen positive subjects participated in the follow-up, again resulting positive for serum p53Abs, and no evidence of
cancer was found in these patients.
Conclusion: The presence of serum p53Abs was found to be associated with smoking level and lung function
impairment, both risk factors of cancer development. However, in our study we have not observed the occurrence
of lung cancer or other cancers in the follow-up of positive subjects, therefore we cannot directly correlate the
presence of serum p53Abs with cancer risk.
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Lung cancer is the leading cause of cancer death in the
world; in the United States, the death rate is 26% in
women and 31% in men [1]. Despite improved therapy,
the survival outcome is often limited by late diagnosis,
when lung cancer is inoperable, and overall 5-year sur-
vival is only 15%. It is, therefore, necessary to search for
new diagnostic tools to identify lung cancer in the early
stages. Mutations in the TP53 tumour suppressor gene
are the most common genetic alterations in human can-
cers [2] and most can lead to the expression of mutant* Correspondence: mattioni@ifo.it
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reproduction in any medium, provided the orp53 proteins with a half-life longer than for the wild
type, which then accumulate in cancer cells. Accumula-
tion has also been found in pre-neoplastic lesions and
normal tissues surrounding the tumours, suggesting that
it occurs early on in cancer progression [3,4]. The accu-
mulation of p53 can in turn induce circulating anti-p53
antibodies (p53Abs), and in fact there is a close correl-
ation between serum p53Abs and p53 overexpression
in the corresponding tissues [5], so that p53Abs can be
considered as early markers for the presence of p53
mutations. Indeed, serum p53Abs were found in patients
with Barrett’s metaplasia of the oesophagus evolving into
dysplasia and cancer as a consequence of chronic reflux;
p53 accumulation especially occurs during transitionl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient characteristics
NORMAL LFT* IMPAIRED LFT
399 276
Age
Median (range), years 56 (26–93) 62 (24–83)
Gender
Male 214 (54%) 169 (61%)
Female 185 (46%) 107 (39%)
Smoking habit
Non-smokers 42 (11%) 44 (16%)
Current smokers 269 (67%) 152 (55%)
Ex-smokers 88 (22%) 80 (29%)
No. of cigarettes smoked per day
≤ 20 241 (60%) 129 (47%)
> 20 114 (29%) 102 (37%)
Missing 2 1
Packs-year
≤ 40 239 (60%) 117 (42%)
> 40 116 (29%) 113 (41%)
Missing 2 2
Years since quitting
≤ 10 35 (9%) 37 (13%)







* LFT, Lung Function Tests.
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p53Abs may predate the diagnosis of oesophageal carcin-
oma [6]. These antibodies have also been showed in serum
of patients with ulcerative colitis, at high risk of develop-
ing colon cancer, and their presence was regarded as an
early marker of malignant progression [7]. Further, serum
p53Abs were detected in workers occupationally exposed
to asbestos, at high risk of cancer, before any clinical evi-
dence of malignancy [8]. Altogether, these data suggest
that serum p53Abs may have predictive value for the sub-
sequent development of cancer. In lung cancer, in particu-
lar, p53 mutations arise early on, since p53 accumulation
was detected in pre-neoplastic lesions such as bronchial
dysplasia [9] and serum p53Abs were found in isolated
cases of both heavy smokers and patients with Chronic
Obstructive Pulmonary Disease (COPD), at high risk of
lung and other tobacco-related cancers, several months
before the diagnosis of cancer [10,11].
Further, a correlation between tobacco smoking and lung
cancer has been demonstrated [12,13] and several studies
have shown increased risk of lung cancer in patients with
COPD [14,15], in particular for the squamous histological
subtype [16]. Cigarette smoking is the main aetiological
factor of both COPD and lung cancer, since cigarette
smoke contains elevated concentrations of oxidants and
carcinogens that can induce persistent lung inflammation
and mutations [17]. Chronic inflammation has been
demonstrated to play a central role in cancer pathogenesis
[18] and recent studies have linked Nuclear Factor (NF)-kB,
major mediator of inflammation, to carcinogenesis [19].
p53 can suppress inflammatory response by inhibiting
NF-kB activity [19] and since it is often mutated by
cigarette smoke, oxidant activation of NF-kB may result in
a chronic imbalance in COPD and lung cancer. In addition,
p53 can reduce COX-2 expression [20], another inflamma-
tory mediator involved in lung cancer development and
progression [21], and loss of p53 activity may contribute to
the persistent elevation of COX-2 in epithelial stroma and
lung cancer cells. Furthermore, COPD frequently shows
squamous metaplasia with dysplastic areas at different
bronchial levels; metaplasia has been correlated with the re-
sponse to chronic inflammation and is associated with p53
mutations [22]. Finally, an increased risk of lung cancer has
also been reported in patients with restrictive lung disease
[23], only slightly associated with tobacco smoking, in
which inflammation of the lung may independently
contribute to the pathogenesis of lung cancer.
Therefore, the aim of our work was to investigate, in a
large prospective study, the incidence of p53Abs, biomar-
kers of p53 mutations, in heavy smokers and patients with
impaired lung function, at high risk of lung cancer and
other cancers, in order to evaluate their relationship with
tobacco smoke exposure and chronic airflow limitation, in
view of a possible role in the early diagnosis of cancer.Methods
Patients
A total of 675 people, including 399 subjects with nor-
mal lung function tests (214 men, 185 women; median
age 56 years, range 26 to 93 years; 42 non-smokers, 88
ex-smokers, 269 current smokers) and 276 patients with
obstructive or restrictive type lung function tests (169
men, 107 women; median age 62 years, range 24 to 83
years; 44 non-smokers, 80 ex-smokers, 152 current smo-
kers; 152 with mild, 73 with moderate and 51 with se-
vere impairment of lung function tests), were evaluated
(Table 1). All people were recruited at the Respiratory
Physiopathology Unit of the Regina Elena National
Cancer Institute, Rome, Italy, between June 2004 and
March 2009. They were enrolled either by a voluntary
pulmonary visit at the Respiratory Physiopathology Unit
or coming from the Tumour Prevention Centre of the
same Institute, because of increased risk of lung cancer.
Regular smokers, ex-smokers and non-smokers were
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nant diseases. The number of non-smokers was small
compared to smokers, because they were only recruited at
the Respiratory Physiopathology Unit along with smokers
and ex-smokers, while only the latter groups, associated
with lung cancer risk, were taken from the Tumour
Prevention Centre. Tobacco smoke exposure was further
evaluated as number of cigarettes smoked per day, years
of tobacco smoking and, in ex-smokers, number of years
since quitting. Ex-smokers were defined as people that
had quit smoking at least 6 months prior to the lung func-
tion tests. All the people enrolled received a routine phys-
ical examination and underwent lung function tests and
low dose CT scans of the chest at the start of the study.
Serum samples were obtained from all subjects at the time
of the lung function tests, thereafter, fifteen people posi-
tive for serum p53Abs, who complied with the follow-up
until June 2011, were tested for serum p53Ab levels with a
median follow-up of 24 months (range 6 to 60 months)
and further evaluated by CT scans of the chest, specialists
or other instrumental examinations suitable for monitor-
ing the development of lung cancer or other cancer types,
such as breast, prostate or colon cancers. The study was
approved by the ethical committee on human experimen-
tation of the promoting institution, Regina Elena National
Cancer Institute, Rome, Italy. All participants in the study
gave their written informed consent.
Serum p53Ab assay
All serum samples were aliquoted, coded, and stored at
−80°C until assays were performed. p53Abs were detected
by a commercially available, highly specific ELISA kit
(Anti-p53 ELISA II kit, PharmaCell, Paris, France), using
micro-titre plates coated either with human recombinant
p53 protein to detect specific p53Abs, or with control pro-
teins to reveal non-specific interactions. The assay was
performed according to the manufacturer’s instructions.
All samples were tested blindly, twice in the same assay.
Absorbance was measured at 450 nm and 620 nm, using a
programmable ELISA reader. p53Ab levels ≥ 1.2 unit/ml
were considered as positive, according to the manufac-
turer’s suggestion; this cut-off was in agreement with other
studies [24].
Usually, p53Abs recognize epitopes in the amino and
carboxyl termini of p53 protein, outside the DNA-binding
domain where most mutations occur, thus identifying
both wild type and mutant p53 proteins; however, p53Abs
to certain types of mutant p53 proteins might not bind to
the wild type recombinant p53 protein used as antigen in
our assay, with the possibility of false negative results.
Furthermore, ELISA shows a high specificity, but a low
sensitivity for serum antibody detection and novel and
more sensitive methods have been developed, such as the
particle agglutination assay [25]. However, ELISA stillretains its value for diagnostic accuracy and easy perfor-
mance in routine diagnostic procedures [26].
Lung function tests
All people were subjected to lung function tests by two spi-
rometers (Altair 1000 and Quark PFT). Lung function tests
were carried out according to the American Thoracic
Society evaluation methods and the values were reported as
percentages of the following parameters: total lung capacity
(TLC), forced vital capacity (FVC), forced expiratory vol-
ume at first second (FEV1) and FEV1/FVC ratio (Tiffenau
index).
Within pulmonary diseases, two types of ventilation
defects are identified by lung function tests: obstructive
or restrictive type. An obstructive defect of pulmonary
ventilation is defined by a Tiffenau index <70%, while
stage of obstruction is specified by the FEV1 value as
follows: mild, FEV1 ≥70%; moderate, FEV1 <70% but
≥60%; moderately severe, FEV1 <60% but ≥50%; severe,
FEV1 <50% but ≥34%; very severe, FEV1 <34%. After
evaluation of these parameters, patients were divided
into three groups: with mild, moderate or severe (includ-
ing moderately severe, severe, and very severe) obstruct-
ive defects.
A restrictive defect of pulmonary ventilation is charac-
terized by TLC reduction; according to this index, the
restrictive defect has been distinguished as: mild, TLC
>70%; moderate, TLC from 70% to 60%; moderately se-
vere, TLC <60% but >50%; severe, TLC from 50% to
34%; very severe, TLC <34%. After evaluation of this par-
ameter, patients were divided into three groups: with
mild, moderate or severe (including moderately severe,
severe, and very severe) restrictive defects.
Statistical analysis
All statistical analyses were performed by using R [27].
Independent variables were first evaluated for uncondi-
tional associations with the dependent variable using a
chi-square test for categorical data and t test for con-
tinuous data. If a continuous variable did not satisfy the
normality assumption, the Wilcoxon rank-sum test was
used. Correlations between independent continuous
variables were assessed based on Pearson’s correlation
coefficient for the normally distributed variables. Corre-
lations between variables that did not satisfy the normal-
ity condition were assessed based on Spearman’s rho
coefficient. Associations between independent categor-
ical and continuous variables were assessed by the t test,
the Wilcoxon rank-sum test, or the exact Wilcoxon rank-
sum test, as appropriate. Multivariate analysis was per-
formed on the variables, resulting statistically significantly
associated in the univariate analysis. In the univariate/
multivariate analysis, P values of <0.05 were considered
statistically significant.
Table 2 Correlation between serum p53Abs and
clinicopathologic parameters
p-valuea
Age (years) (< 58 / ≥ 58)
Negative 308 / 328 (48% / 52%) 0.502
Positive 19 / 15 (56% / 44%)
Missing 5
Gender Male / Female
Negative 359 / 281 (56% / 44%) 0.202
Positive 24 / 11 (69% / 31%)
No. of cigarettes per day (> 20 / ≤ 20)
Negative 197 / 356 (36% / 64%) 0.019*
Positive 19 / 14 (58% / 42%)
Packs-year (> 40 / ≤ 40)
Negative 211 / 341 (38% / 62%) 0.092#
Positive 18 / 15 (55% / 45%)
LFT impairment Moderate-Severe / Normal-Mild
Negative 113 / 527 (18% / 82%) 0.068#
Positive 11 / 24 (31% / 69%)
aCalculated by chi-square test;* p < 0.05, # p < 0.10.
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Sera from 675 subjects, including non-smokers, ex-
smokers and current smokers, with normal or impaired
lung function tests, were evaluated for the presence of
p53Abs. Our results showed that 5.2% of them (35 out
of 675) had significant levels of serum p53Abs, with a
median value of 3.5 units/ml (range 1.2 to 65.3 units/
ml). No difference was found by age or gender. An asso-
ciation between serum p53Abs and smoking habit has
been observed, although not statistically significant: two
out of 86 non-smokers (2.3%), 23 out of 421 current
smokers (5.5%) and ten out of 168 ex-smokers (6.0%)
were positive for p53Abs; furthermore, in subjects with
normal lung function tests, none of the 42 non-smokers
(0%), fifteen out of 269 current smokers (5.6%) and six
out of 88 ex-smokers (6.8%) had p53Abs, while in
patients with impaired tests, two of the 44 non-smokers
(4.6%), eight out of 152 current smokers (5.3%) and four
out of 80 ex-smokers (5.0%) resulted p53Ab positive,
suggesting that the association of serum p53Abs with
smoking habit was more evident in cases of normal lung
function. Airway inflammation has a part also in lung
function decline independent of smoking, as observed in
asthma and pulmonary fibrosis. Through oxidative DNA
damage, this inflammation can promote p53 mutation
and overexpression in the surrounding lung cells, with
subsequent induction of serum p53Abs; this might be
the reason why we found two p53Ab positive patients
amongst the non-smokers with impaired lung function.
A statistically significant correlation between the rate of
p53Ab positive subjects and the number of cigarettes
smoked per day was found (p = 0.019), while a trend of
increase with packs-year was observed (p = 0.092,
Table 2).
We then considered the correlation between serum
p53Abs and impairment of lung function of either the
obstructive or restrictive type, classified as mild, moder-
ate, and severe. Twenty one of the 399 subjects with
normal lung function tests (5.3%) and fourteen of the
276 patients with altered tests (5.1%) were positive for
p53Abs. However, in the latter group, three out of 152
patients with mild (2.0%), eight out of 73 with moderate
(11.0%) and three out of 51 with severe (5.9%) impair-
ment of lung function had p53Abs. Then, we examined
the correlation between serum p53Abs and, on one
hand, subjects with normal lung function or mildly
altered tests and, on the other hand, patients with mod-
erate to severe impairment of lung function. A higher
rate of serum p53Abs was found as a trend (p = 0.068) in
patients with moderate to severe impairment of lung
function tests, in comparison to subjects with normal or
mildly altered tests (Table 2), this correlation was con-
firmed by a multivariate analysis (p = 0.045). Further-
more, the multivariate analysis showed the lung functiontest impairment to be a statistically significant predictor
of serum p53Ab detection, but not other parameters,
such as age, gender or smoking habit.
We further investigated whether there were differences
in the presence of serum p53Abs between people with
normal lung function tests and patients with altered lung
function tests with regard to age, gender, number of cigar-
ettes per day and packs-year (Table 3). No difference was
found by age or gender; on the other hand, there was a
significant correlation of serum p53Abs with cigarettes
smoked per day (p = 0.001) and an increased trend with
packs-year (p = 0.081) for the normal lung function group,
while no correlation was observed in patients with altered
lung function tests.
Further, median serum p53Ab levels were calculated to
evaluate whether there was any correlation with clinico-
pathologic features such as age, gender, smoking status
and lung function impairment, but no correlation was
found as reported in Table 4. With regard to quitting
smoking, no significant difference in p53Ab levels was
observed over time, presumably due to the small number
of positive subjects; in fact, four positive subjects were
found out of 72 ex-smokers, who had quit smoking
for ≤10 years, and three positive subjects out of 54 ex-
smokers, who had quit for >10 years, with a median serum
p53Ab level of 4.1 and 3.9 units/ml, respectively.
Finally, due to follow-up loss, only fifteen subjects posi-
tive for serum p53Abs were further assessed for the pres-
ence of these Abs, with a median follow-up of 24 months
(range 6 to 60 months), again resulting positive for
p53Abs, and no one has shown any sign of incipient
Table 3 Correlation between serum p53Abs and clinicopathologic parameters, distinguishing between subjects with
normal or altered LFT
Normal LFT p-valuea Altered LFT p-valuea
Age (years) (< 58 / ≥ 58) (< 58 / ≥ 58)
Negative 221/154 (59%/ 41%) 0.233 87/174 (33%/67%) 0.938
Positive 15/5 (75%/25%) 4/10 (29%/71%)
Missing 4 1
Gender Male / Female Male / Female
Negative 202/176 (53%/47%) 0.915 157/105 (60%/40%) 0.136
Positive 12/9 (57%/43%) 12/2 (86%/14%)
No. of cigarettes per day (> 20 / ≤ 20) (> 20 / ≤ 20)
Negative 100/234 (30%/70%) 0.001* 97/122 (44%/56%) 0.904
Positive 14/7 (67%/33%) 5/7 (42%/58%)
Packs-year (> 40 / ≤ 40) (> 40 / ≤ 40)
Negative 105/229 (31%/69%) 0.081# 106/112 (49%/51%) 0.720
Positive 11/10 (52%/48%) 7/5 (58%/42%)
aCalculated by chi-square test; * p < 0.05, # p < 0.10.
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carried out to verify the development of lung cancer or
other cancers, such as breast, prostate or colon cancers.Discussion
In the present investigation, we detected significant
levels of serum p53Abs in 35 (5.2%) out of 675 subjects,
including non-smokers, ex-smokers and current smo-
kers, with normal or impaired lung function tests. With
regard to smoking status, a trend, although not statisti-
cally significant, was found in the frequency of p53Abs,
increasing from non-smokers (2.3%) to current smokers
(5.5%) and ex-smokers (6.0%); the differences were more
evident in subjects with normal lung function tests,Table 4 Correlations between median serum p53Ab levels
and clinicopathologic parameters
Median serum p53Ab levels
(units/ml)
p-valuea
Age (years) (< 58 / ≥ 58)
3.5 / 3.6 0.510
Gender Male / Female
3.55 / 2.5 0.582
No. of cigarettes per day (> 20 / ≤ 20)
3.5 / 2.5 0.232
Packs-year (> 40 / ≤ 40)
3.55 /2.5 0.143
LFT impairment Moderate-Severe / Normal-Mild
5.0 / 8.0 0.371
LFT impairment Mild to Severe / Normal
4.6 / 7.8 0.285
aCalculated by chi-square test.while nil in patients with impaired tests. Further, we
showed a significant correlation between the presence of
serum p53Abs and the number of cigarettes smoked per
day, while an increased trend between p53Abs and
packs-year was observed. Furthermore, a higher rate of
p53Ab positive sera was found as a trend in patients
with moderate to severe impairment of lung function,
compared to subjects with normal or mildly altered lung
function. We also considered the difference in serum
p53Abs between subjects with normal lung function and
patients with altered lung function with regard to the
number of cigarettes smoked per day and packs-year and
found a significant correlation of p53Abs with cigarettes
smoked per day and an increased trend with packs-year
in the normal lung function group, while no correlation
was observed in patients with altered lung function tests.
Finally, none of the follow-up p53Ab positive subjects
showed development of lung cancer or other cancers,
such as breast, prostate and colon cancers.
Cigarette smoking is closely correlated with p53 muta-
tions. Husgafvel-Pursiainen and co-authors [28] observed
that the frequency of p53 mutations increased from non-
smokers to ex-smokers, reaching the highest rate in
current smokers. Li and co-authors [29] reported a similar
trend with frequency of serum p53Abs that increased
from non-smokers to ex-smokers and current smokers,
with heavy smokers having the highest prevalence. Our
study also shows that current smokers (5.5%) and ex-
smokers (6.0%) have higher frequencies of serum p53Abs
than non-smokers (2.3%). Lubin and co-authors [10] and
Trivers and co-authors [11] found that serum p53Abs can
be detected in ex-smokers and current smokers even 15
months before the diagnosis of lung, breast, and prostate
cancers, suggesting that serum p53Abs, closely associated
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of tobacco-related cancers.
Impaired lung function has also been associated with
an increased risk of lung cancer. In a meta-analysis,
Wasswa-Kintu and co-authors [14] observed that, inde-
pendent of cigarette smoking, reduced FEV1 increased
lung cancer risk in the general population; in addition,
patients with the worst lung function showed the highest
risk, while subjects with normal lung function had the
lowest risk. Furthermore, even small differences in FEV1
significantly increased the risk of lung cancer; finally, the
risk was amplified in women. In a very large prospective
study, Purdue and co-authors [23] found an increased
risk of lung cancer in patients with either obstructive
or restrictive impairment of lung function. In our inves-
tigation, a higher rate of serum p53Abs was found in
patients with the worst lung function alterations of
either obstructive or restrictive type, thus confirming
that p53Abs may be associated with patients at increased
risk of lung cancer. Impaired lung function may derive
through conditions that increase the risk of lung cancer,
such as inflammation of the airways, which plays a role
in smokers and patients with asthma or COPD [30]; on
the other hand, inflammatory processes responsible for
lung restriction may also contribute to lung cancer patho-
genesis [31]. Since p53 can function as an inhibitor of
inflammation [19], mutant p53 proteins may be involved
in deregulated inflammation contributing to the patho-
genesis of lung cancer and other cancers and then serum
p53Abs may be early markers of tumor development in
people at high risk of cancer, such as patients with
impaired lung function. However, since this study shows
there was only a small number of p53Ab positive subjects
who complied with the follow-up, and neither lung cancer
nor other cancers were observed, we cannot correlate the
presence of serum p53Abs with cancer risk.
Other well defined markers of lung cancer are the
Kirsten rat sarcoma viral oncogene homolog (KRAS)
and Epidermal growth factor receptor (EGFR). KRAS is
involved in several signalling pathways and mutations in
this gene may lead to cancer development. In fact, KRAS
mutations are present up to 30% in non-small cell lung
cancers (NSCLC). They are found prevalently on codon
12 and appear early in cancer development; furthermore,
in some tumors they have been detected in blood before
clinical diagnosis [32]. On the other hand, EGFR is
highly expressed in various cancers, including lung
cancer. EGFR is a member of the family of EGF tyrosine
kinase receptors and upon ligand binding activates
several intracellular pathways. A soluble fragment of the
EGFR extracellular ligand domain can be detected by
ELISA in the blood of cancer patients, including NSCLC
patients, and may also be elevated at an early stage of
carcinogenesis in asbestosis patients [33]. Thus, KRASand EGFR might have a role as markers of lung function
impairment that may reflect cancer risk. Of interest,
other proteins can be used to detect lung function
impairment, such as Fibrinogen, Neutrophil gelatinase
associated lipocalin, Extracellular newly identified RAGE-
binding protein and Heparin-binding EGF-like growth
factor, showing significantly different serum levels when
comparing mild/moderate and severe/very severe COPD
patients to smoking and non-smoking controls [34].
Conclusions
Detection of serum p53Abs in people at high risk of lung
cancer and other cancers, such as heavy smokers and
patients with impaired lung function, shows a correl-
ation with cigarettes smoked per day, packs-year and the
worst impairment of lung function tests. However, in
our study, no correlation was observed between serum
p53Abs and cancer risk.
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